View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 14, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	FLGT
Entity Registrant Name	Fulgent Genetics, Inc.
Entity Central Index Key	0001674930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		17,676,256

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash	$ 8,205	$ 489
Trade accounts receivable, net of allowance for doubtful accounts of $48 and $75, respectively	4,406	2,118
Other current assets	4,883	314
Current assets of discontinued operations		9
Total current assets	17,494	2,930
Fixed assets, net	5,178	2,469
Deferred tax asset	86
Non-current assets of discontinued operations		433
Total noncurrent assets	5,264	2,902
Total assets	22,758	5,832
Current liabilities
Accounts payable	3,286	314
Accrued liabilities	471	199
Other current liabilities	1,253
Current liabilities of discontinued operations		173
Total current liabilities	5,010	686
Deferred tax liability	503
Total liabilities	5,513	686
Commitments and contingencies (Note 9)
Stockholders’/ Members’ equity
Members' equity 56,000 Class D and 51,000 Class P preferred units authorized, issued and outstanding, 44,000 Class D and 49,000 Class P common units authorized and 34,000 Class D and 45,000 Class P common units issued and outstanding, at December 31, 2015 (Note 10)		58,306
Common stock, $0.0001 par value per share, 200,000 shares authorized, 12,846 shares issued and outstanding at September 30, 2016	1
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at September 30, 2016
Additional paid-in capital	73,211
Accumulated deficit	(55,967)	(53,160)
Total Stockholders’/ Members’equity	17,245	5,146
Total liabilities and stockholders’/ members’ equity	$ 22,758	$ 5,832

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Allowance for doubtful accounts receivable	$ 48	$ 75
Common stock, par value	$ 0.0001
Common stock, shares authorized	200,000,000
Common stock, shares issued	12,846,000
Common stock, shares outstanding	12,846,000
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	1,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Class D Preferred Units
Members' equity, preferred units, authorized		56,000,000
Members' equity, preferred units, issued		56,000,000
Members' equity, preferred units, outstanding		56,000,000
Class P Preferred Units
Members' equity, preferred units, authorized		51,000,000
Members' equity, preferred units, issued		51,000,000
Members' equity, preferred units, outstanding		51,000,000
Class D Common Units
Members' equity, common units, authorized		44,000,000
Members' equity, common units, issued		34,000,000
Members' equity, common units, outstanding		34,000,000
Class P Common Units
Members' equity, common units, authorized		49,000,000
Members' equity, common units, issued		45,000,000
Members' equity, common units, outstanding		45,000,000

Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Income Statement [Abstract]

Revenue

$ 5,011

$ 2,905

$ 12,422

$ 6,675

Cost of revenue

2,143

918

4,858

2,343

Gross profit

2,868

1,987

7,564

4,332

Operating expenses:

Research and development

1,523

311

2,739

782

Selling and marketing

893

280

1,671

757

General and administrative

1,147

216

3,494

461

Total operating expenses

3,563

807

7,904

2,000

Operating income (loss)

(695)

1,180

(340)

2,332

Interest and other income (expense)

(5,444)

Income (loss) before income taxes

(690)

1,180

(5,784)

2,352

Provision for income taxes

417

Income (loss) from continuing operations

(1,107)

1,180

(6,201)

2,352

Income (loss) from discontinued operations

(821)

(2,121)

Net income (loss)

$ (1,107)

$ 359

$ (6,160)

$ 231

Basic and diluted income (loss) per common share:

Continuing operations—common stock

$ (0.44)

$ 0

^[1]

$ (1.17)

$ 0

^[1]

Continuing operations:

Weighted-average common shares—outstanding—basic and diluted

12,846

12,455

[1]	Basic and diluted income (loss) per common share was calculated prospectively from the date the Class D common units were issued in the October 2015 Recapitalization.

Consolidated Statements of Stockholders'/ Members' equity (unaudited) - 9 months ended Sep. 30, 2016 - USD ($) $ in Thousands	Total	Members' Equity	Stockholders' Equity	Additional Paid-In Capital	Accumulated Deficit	Class D-2 Convertible Preferred Units	Class D-2 Convertible Preferred Units Members' Equity	Class D-1 Preferred Units	Class D-1 Preferred Units Members' Equity	Class D-1 Preferred Units Accumulated Deficit	Class D Common Units	Class D Common Units Members' Equity	Class D Common Units Accumulated Deficit
Beginning Balance at Dec. 31, 2015	$ 5,146	$ 58,306			$ (53,160)
Beginning Balance, Shares at Dec. 31, 2015		186,000,000
Split-off of Pharma business	(490)	$ (12,390)			11,900
Split-off of Pharma business, Shares		(96,000,000)
Issuance of convertible preferred units (net of $185 issuance costs)						$ 32,452	$ 32,452
Issuance of convertible preferred units (net of $185 issuance costs), Shares							15,395,000
Repurchase and retirement								$ (1,663)	$ (1,663)		$ (6,587)	$ (1,767)	$ (4,820)
Repurchase and retirement, Shares									(4,618,000)			(5,645,000)
Deemed dividend on retirement								(3,727)		$ (3,727)
Equity-based compensation (Pre-Reorganization)	2,978	$ 2,978
Equity-based compensation (Pre-Reorganization), Shares		2,500,000
Distribution to preferred unitholder								$ (4,592)	$ (4,592)
Tax distribution to common and preferred unitholders											$ (1,253)	$ (1,253)
Reorganization (Note 1)		$ (72,071)	$ 1	$ 72,070
Reorganization, Shares (Note 1)		(97,632,000)	12,846,000
Equity-based compensation (Post-Reorganization)	1,141			1,141
Net loss	(6,160)				(6,160)
Ending Balance at Sep. 30, 2016	$ 17,245		$ 1	$ 73,211	$ (55,967)
Ending Balance, Shares at Sep. 30, 2016	12,846,000		12,846,000

Consolidated Statements of Stockholders'/ Members' equity (Parenthetical) (unaudited) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Class D-2 Convertible Preferred Units
Preferred units issuance cost, net	$ 185

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from operating activities:
Net income (loss)	$ (6,160)	$ 231
Income (loss) from discontinued operations	41	(2,121)
Income (loss) from continuing operations	(6,201)	2,352
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity-based compensation	4,119
Depreciation and amortization	750	385
Gain on disposal of fixed assets		(20)
Provision for bad debt	(27)	1
Deferred income taxes	417
Fair value adjustment recorded upon issuance of D-2 preferred units	5,472
Changes in operating assets and liabilities:
Increase in accounts receivable	(2,261)	(1,276)
Increase in other current assets	(400)	(189)
Increase in accounts payable	1,578	356
(Decrease) increase in accrued liabilities	(265)	36
Cash provided by continuing operations	3,182	1,645
Cash used in discontinued operations	(31)	(2,079)
Net cash provided by (used in) operating activities	3,151	(434)
Cash flow from investing activities:
Proceeds from disposal of fixed assets		70
Purchases of fixed assets	(3,379)	(1,875)
Cash used in continuing operations	(3,379)	(1,805)
Cash used in discontinued operations		(125)
Net cash used in investing activities	(3,379)	(1,930)
Cash flow from financing activities:
Cash distributed in split-off of Pharma business	(159)
Capital contributions		3,500
Return of capital contribution	(4,592)
Payment of initial public offering costs	(2,318)
Proceeds from issuance of D-2 units	27,165
Repurchase and retirement of Class D-1 preferred and Class D common units	(11,976)
Issuance costs of Class D-2 preferred units	(185)
Net cash provided by financing activities	7,935	3,500
Net increase in cash	7,707	1,136
Cash balance at beginning of period	498	172
Cash balance at end of period	8,205	1,308
Supplemental cash flow information:
Fixed assets included in accounts payable	97	$ 130
Tax distribution to Class D common and preferred unitholders in Other current liabilities	1,253
Deferred initial public offering costs included in accounts payable	$ 1,852

Condensed Consolidated Statements of Cash Flows (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015
Statement Of Cash Flows [Abstract]
Cash from discontinued operations, beginning	$ 9	$ 0	$ 0
Cash from discontinued operations, ending	$ 0	$ 9	$ 0

Overview and Basis of Presentation

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiary (collectively referred to as the “Company,” unless otherwise noted or the context otherwise requires), is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. The Company’s current test menu offers single-gene tests and pre-established, multi-gene, disease-specific panels that collectively test for many genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s existing customer base consists primarily of hospitals and medical institutions, which are frequent and high-volume users of genetic tests.

Background and Reorganization

The Company was incorporated in the State of Delaware on May 13, 2016. On August 2, 2016, pursuant to the approval of the board of directors of the Company, the Company changed its name from Fulgent Diagnostics, Inc. to Fulgent Genetics, Inc. Prior to the Reorganization, as defined and described below, the Company had no material assets and had not conducted any activities other than those incidental to its incorporation and preparation for the initial public offering of its common stock. Following the Reorganization, the Company is a holding company with no material assets other than 100% of the equity interests in Fulgent LLC, and Fulgent LLC is considered the Company’s predecessor for accounting purposes and its financial statements for all periods prior to completion of the Reorganization constitute the Company’s historical financial statements.

On September 30, 2016, the Company completed a reorganization pursuant to which Fulgent Therapeutics LLC, a California limited liability company (referred to, together with its former subsidiary unless otherwise noted or the context otherwise requires, as “Fulgent LLC”), became a wholly owned subsidiary of the Company (the “Reorganization”). For purposes of these notes and the accompanying condensed consolidated financial statements: (i) Fulgent LLC’s operating agreement, as amended from time to time, is referred to as the “Operating Agreement;” (ii) Fulgent LLC’s equity holders are referred to as “members;” (iii) Fulgent LLC’s authorized, issued and outstanding equity interests prior to the Reorganization are referred to as “units” and consisted of Class D common units and Class D-1 and Class D-2 preferred units; (iv) certain of Fulgent LLC’s Class D common units outstanding prior to the Reorganization constituted profits interests, which are a type of equity award containing a participation threshold (which is sometimes referred to as a “profits interest threshold”) that entitled the recipient of the award to participate in the value of Fulgent LLC only to the extent it appreciated from and after the grant date of the award; and (v) prior to the Reorganization, Fulgent LLC was managed by its Manager, Ming Hsieh, who was also Fulgent LLC’s controlling equity holder. In the Reorganization, each outstanding 7.6 units of Fulgent LLC were cancelled in exchange for one share of the Company’s common stock, such that (i) all outstanding Class D common units of Fulgent LLC (including Class D common units that constitute profits interests) were cancelled in exchange for an aggregate of 4,060 shares of the Company’s common stock; (ii) all outstanding Class D-1 preferred units of Fulgent LLC were cancelled in exchange for an aggregate of 6,761 shares of the Company’s common stock; (iii) all outstanding Class D-2 preferred units were cancelled in exchange for an aggregate of 2,026 shares of the Company’s common stock; (iv) all outstanding options to acquire common units of Fulgent LLC were cancelled in exchange for equivalent options to acquire up to an aggregate of 591,112 shares of the Company’s common stock, and all such options became immediately exercisable to the extent vested; and (v) all outstanding restricted share units relating to common units of Fulgent LLC were cancelled in exchange for equivalent restricted stock units (“RSUs”) relating to 65,789 shares of the Company’s common stock. The Reorganization was accounted for as a common control transaction and no gain or loss was recorded.

Initial Public Offering

On October 4, 2016, the Company completed the initial public offering of its common stock (the “IPO”), in which it issued and sold an aggregate of 4,830 shares of common stock (including 630 shares issued and sold on October 7, 2016 pursuant to the underwriters’ exercise in full of their option to purchase additional shares) at a public offering price of $9.00 per share. The Company received net proceeds of approximately $36,258, after deducting underwriting discounts and commissions of $3,043 and other offering expenses paid or payable by the Company of approximately $4,169. The shares issued and sold in the IPO were registered under the Securities Act of 1933, as amended, on a registration statement on Form S-1 (File No. 333- 213469), as amended (the “Registration Statement,” and the final prospectus dated September 28, 2016 included in the Registration Statement, the “Prospectus”). The issuance of shares in the IPO occurred subsequent to September 30, 2016 and therefore is not reflected in the results of operations or financial position of the Company as set forth in these notes and the accompanying condensed consolidated financial statements.

Unaudited Interim Financial Information

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. These interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). These financial statements have been prepared on the same basis as the audited consolidated financial statements for the fiscal year ended December 31, 2015 and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year. The accompanying condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the disclosures required by GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission on September 28, 2016 (the “Prospectus”).

Discontinued Operations

In April 2016, Fulgent LLC’s Operating Agreement was amended and restated to provide for the distribution of its wholly owned subsidiary, Fulgent Pharma LLC (“Fulgent Pharma”), in full redemption and cancellation of its former Class P preferred and common units (collectively, the “Class P units”). On April 4, 2016, the Company completed the split-off of Fulgent Pharma and the pharmaceutical business operated by Fulgent Pharma (the “Pharma business”) by redeeming all of the then-outstanding Class P units and distributing to each holder of Class P units substantially identical shares of Fulgent Pharma and causing Fulgent Pharma to assume all then-outstanding options to purchase Class P units. All Class P units were immediately cancelled upon redemption. The split-off of the Pharma business was a pro-rata distribution to all of the holders of Class P units, but did not involve the holders of Fulgent LLC’s Class D units. The Manager and controlling unitholder of Fulgent LLC prior to the Reorganization, Mr. Hsieh, is the Manager and controlling unitholder of Fulgent Pharma. Therefore, Fulgent LLC concluded that the split-off transaction should be accounted for as a common control transaction and the recorded amount of Fulgent Pharma’s net assets was transferred to the holders of Class P units and no gain or loss was recorded.

The split-off of the Pharma business is presented as discontinued operations in the accompanying condensed consolidated financial statements for all periods presented. Significant asset and liability categories of the Pharma business are disclosed on the accompanying condensed consolidated balance sheet. Significant assets and liabilities of the discontinued operations consist of fixed assets and accounts payable.

The major components of statements of operations data comprising the income (loss) on discontinued operations are as follows:

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2016		2015			2016			2015
Operating expenses:
Research and development	$	-	$	732		$	350		$	1,220
General and administrative		-		89			9			900
Total operating expenses		-		821			359			2,120
Operating Income (loss)		-		(821	)		(359	)		(2,120	)
Interest and other income (expense)		-		-			400			(1	)
Income (loss)	$	-	$	(821	)	$	41		$	(2,121	)

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements for the year ended December 31, 2015, which are included in the Prospectus. Except as described below, no such policies materially changed during the nine months ended September 30, 2016. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors that management believes to be reasonable under the circumstances. Actual results could differ from these estimates. Significant items subject to such estimates and assumptions include revenue recognition criteria, the fair value of equity-based awards, accounts receivable and allowances for doubtful accounts, the useful lives of fixed assets and estimates of tax liabilities. Reporting Segment and Geographic Information Reporting segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its CEO. The Company views its operations and manages its business in one reporting segment. Income Taxes Income taxes are accounted for under the asset and liability method. The Company provides for federal, state and foreign income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense. Prior to the Reorganization, Fulgent LLC was organized as a limited liability company and its members elected to have Fulgent LLC treated as a partnership for income tax purposes. All taxable income or loss and tax credits generally were reflected in the personal income tax returns of the Fulgent LLC’s members. Accordingly, no provision for federal and state income taxes was provided in the accompanying consolidated financial statements prior to the Reorganization. Pursuant to the Reorganization, the Company is a taxable entity. The change in tax status resulted in the recognition of a deferred tax asset in the amount of $86 and a deferred tax liability in the amount of $503 representing the initial temporary differences at the time of the change in status. The most significant components of the deferred tax asset and liability were the result of differences in book and tax depreciation and equity-based compensation. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance The FASB continues to address certain implementation issues and clarify certain core revenue recognition principles of ASU 2014-09. In July 2015, the FASB voted to delay the effective date of this standard such that ASU 2014-09, as amended, will be effective for the Company for annual and interim periods beginning after December 15, 2017. Early adoption of the standard is permitted for annual periods beginning after December 15, 2016. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company is evaluating the effects of this standard on its financial position, results of operations and cash flows. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”), which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, including a provision that requires equity investments (except for investments accounted for under the equity method of accounting) to be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 is effective for the Company in the first quarter of 2018, with early adoption permitted. The Company is currently evaluating the effect that ASU 2016-01 will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The update is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for interim and annual reporting periods beginning with the year ending December 31, 2019. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows. The standard clarifies the way certain cash receipts and cash payments are classified with the objective of reducing the existing diversity in practice. The standard is effective for fiscal years and interim periods beginning after December 15, 2017. Early adoption is permitted for all periods beginning after December 15, 2016. The Company is currently evaluating the impact of adopting this standard.

Income (Loss) Per Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Income (Loss) per Share

Note 3. Income (Loss) per Share

The income (loss) per share for the periods ended September 30, 2016 were computed as if the Reorganization, including the exchange of 1 share of common stock for every 7.6 Fulgent LLC unit had occurred on January 1, 2016. Income (loss) per share prior to the October 2015 Recapitalization is not presented. The following table presents the calculation of basic and diluted income (loss) per share for the three and nine months ended September 30, 2016:

	Three Months Ended								Nine Months Ended
	Continuing Operations			Discontinued Operations		Total			Continuing Operations			Discontinued Operations		Total
Income (loss)	$	(1,107	)	$	0	$	(1,107	)	$	(6,201	)	$	41	$	(6,160	)
Deemed dividend on redemption of Class D-1 preferred unit						$	0		$	(3,727	)			$	(3,727	)
Distribution to Class D-1 preferred unitholder	$	(4,592	)			$	(4,592	)	$	(4,592	)			$	(4,592	)
Income (loss) allocable to common shareholders	$	(5,699	)	$	0	$	(5,699	)	$	(14,520	)	$	41	$	(14,479	)
Income (loss) allocated to common shareholders	$	(5,699	)						$	(14,520	)
Income (loss) allocated to Class P common units													18
Income (loss) allocated to Class P preferred units													23
Weighted-average common shares—outstanding, basic and diluted		12,846			—					12,455			—
Weighted-average Class P common units outstanding, basic and diluted		—			—					—			13,522
Weighted-average Class P preferred units outstanding, basic and diluted		—			—					—			17,682
Income (loss) per common share from continuing operations, basic and diluted	$	(0.44	)		—				$	(1.17	)		—
Income per Class P common unit, basic and diluted		—			—					—			—
Income per Class P preferred unit, basic and diluted		—			—					—			—

On April 4, 2016, Fulgent LLC completed the split-off of the Pharma business. The financial condition and results of the Pharma business are included in the accompanying condensed consolidated financial statements as discontinued operations for all periods presented, and the weighted -average Class P units related to the Pharma business were computed through the separation date of April 4, 2016.

The following securities have been excluded from the calculation of diluted income (loss) per share for all periods presented because their effect would have been anti-dilutive:

	Three Months Ended				Nine Months Ended
	Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Common share options		591		—		591		—
Common share restricted stock units		66				66
Class P common unit options		—		—		—		1,810

The anti-dilutive shares disclosed above were calculated using the treasury stock method. During the three and nine month periods ended September 30, 2016, the Company had common share options and restricted units that were excluded from the weighted average share calculation for continuing operations due to the Company’s net loss positions. During the nine month period ended September 30, 2016, the Company had Class P common unit options that were excluded from the weighted average share calculation for discontinued operations as the shares were determined to be anti-dilutive using the treasury method.

Fixed Assets

9 Months Ended

Sep. 30, 2016

Property Plant And Equipment [Abstract]

Fixed Assets

Note 4. Fixed Assets

Major classes of fixed assets were as follows:

	Useful Lives	September 30, 2016			December 31, 2015
Computer hardware	3 Years	$	1,003		$	601
Computer software	3 Years		318			176
Machinery and equipment	5 Years		177			210
Medical lab equipment	5 Years		4,678			2,016
General equipment	3 Years		59			59
Furniture and fixtures	5 Years		86			51
Leasehold improvements	Shorter of lease term or estimated useful life		485			256
Sub-Total		$	6,806		$	3,369
Accumulated depreciation			(1,628	)		(900	)
		$	5,178		$	2,469

Depreciation expense on fixed assets totaled $304 and $171 in the three months ended September 30, 2016 and 2015, respectively. Depreciation expense on fixed assets totaled $750 and $385 in the nine months ended September 30, 2016 and 2015, respectively.

Other Current Assets

9 Months Ended

Sep. 30, 2016

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

Note 5. Other Current Assets

Other current assets consisted of the following:

	September 30, 2016		December 31, 2015
Deferred initial public offering costs	$	4,169	$	—
Reagents		525		212
Prepaid expenses		183		65
Payroll tax refund		6		37
Total	$	4,883	$	314

Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Other Current Liabilities	9 Months Ended
Other Current Liabilities	Sep. 30, 2016
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	Note 6. Other Current Liabilities The Company has accrued tax distributions of $1.3 million to the former LLC members as of September 30, 2016 based on the income tax liabilities of such former members attributable to Fulgent LLC’s 2016 net taxable income through the date of the Reorganization, as determined by the Manager in accordance with the Third Amended and Restated Operating Agreement for Fulgent LLC, and presented such in Other Current Liabilities on the accompanying condensed consolidated balance sheet.

Reporting Segment and Geographic Information

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. All long-lived assets are located in the United States.

Revenue by region was as follows:

		For the Three Months Ended September 30,			For the Nine Months Ended September 30,
	2016		2015		2016		2015
Revenue:
United States	$	2,147	$	1,559	$	6,283	$	3,500
Foreign:
Canada		937		801		2,676		2,176
China		1,148				1,148
Other Countries		779		545		2,315		999
	$	5,011	$	2,905	$	12,422	$	6,675

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Major Customers and Accounts Receivable	9 Months Ended
Major Customers and Accounts Receivable	Sep. 30, 2016
Risks And Uncertainties [Abstract]
Major Customers and Accounts Receivable	Note 8. Major Customers and Accounts Receivable The Company had a customer whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balance individually represented 10% or more of the Company’s total accounts receivable, as follows: For the three months ended September 30, 2016 and 2015, one customer accounted for 23% and zero of revenue, respectively. For the nine months ended September 30, 2016 and 2015, the Company did not have a customer whose revenue individually represented 10% or more of the Company’s total revenue. At September 30, 2016, one customer accounted for 26% of the Company’s total accounts receivable. At December 31, 2015, there were no customers that accounted for 10% or more of the Company’s total accounts receivable.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Operating Leases The Company has commitments under non-cancelable operating leases of varying terms and duration for its headquarters located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”) and licensed by the State of California Department of Public Health (“CA DPH”). Rent expense for the three months ended September 30, 2016 and 2015 was $55 and $47, respectively. Rent expense for the nine months ended September 30, 2016 and 2015 was $179 and $115, respectively. Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Members' / Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Members’ / Stockholders' Equity

Note 10. Members’ / Stockholders' Equity

Reorganization

Upon completion of the Reorganization on September 30, 2016, all of Fulgent LLC’s outstanding units were cancelled in exchange for shares of the Company’s common stock, at a ratio of 7.6 units of Fulgent LLC cancelled for each one share of the Company’s common stock.

The following is a summary of the units of Fulgent LLC that were cancelled in exchange for shares of the Company’s common stock:

	Pre-Reorganization
Class D-1 preferred units		51,382
Class D-2 preferred units		15,395
Class D common units		2,500
Class D common units — profit interests		28,355
		97,632

The units set forth in the table above were cancelled in exchange for an aggregate of 12,846 shares of the Company’s common stock. The members’ equity balance of $72 million was reclassified into common stock and additional paid-in capital in the accompanying condensed consolidated balance sheet as of September 30, 2016.

Certificate of Incorporation

In accordance with the Company’s certificate of incorporation, the Company is authorized to issue 200,000 shares of common stock, with a par value of $0.0001 per share, and 1,000 shares of preferred stock, with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share held on all matters submitted to a vote of its stockholders. Holders of the Company’s common stock have no cumulative voting rights. Further, as of September 30, 2016, holders of the Company’s common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to the Company’s common stock. Upon liquidation, dissolution or winding-up of the Company, holders of the Company’s common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company’s common stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s board of directors. As of September 30, 2016, there were no outstanding shares of preferred stock.

Distributions

The Company has accrued a tax distribution to Class D common and preferred unitholders as of September 30, 2016 in the amount of $1.3 million. The amount was based on income allocable to the LLC up to the Reorganization date. In addition, in September 2016, the Company distributed $4.6 million to Mr. Hsieh in his capacity as a member of Fulgent LLC as a return of capital contribution.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Equity-Based Compensation

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

Note 11. Equity-Based Compensation

Equity-based compensation expense to employees is measured based on the fair value of the awards on the grant date and recognized in the Company’s consolidated statements of operations over the period during which the employee is required to perform services in exchange for the award (generally the vesting period of the award). Compensation expense for awards with both a service and performance condition is recognized over the period required to achieve both conditions using the accelerated attribution method. The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The Company measures the fair value of RSUs based on the fair value of the underlying shares on the date of grant. For awards of Fulgent LLC units subject to a profits interest threshold, the fair value is measured using the Black-Scholes option valuation model.

Prior to the Reorganization, the Company’s employees and other service providers were granted awards under the Fulgent Therapeutics LLC Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”), which provided for the issuance of equity-based awards to eligible employees, directors and consultants. These awards generally consisted of options, restricted share units and units subject to a profits interest threshold. Options granted under the 2015 Plan typically vested over four years and expired 10 years from the date of grant, and were not exercisable, whether or not vested, until the earlier of a liquidity event or incorporation, each as defined in the 2015 Plan. Because the options were subject to both a service condition (as set forth in their vesting schedules) and a performance condition (the occurrence of a qualifying liquidity event or incorporation), no equity-based compensation expense was recognized for these options until the performance condition was deemed to have been satisfied. Restricted share units granted under the 2015 Plan typically vested over four years. Awards of units subject to profits interest thresholds were typically fully vested at the date of grant.

In connection with the Reorganization, the Company approved its 2016 Omnibus Incentive Plan (the “2016 Plan”), which provides for the issuance of up to an aggregate of 2,038 shares of the Company’s common stock pursuant to awards granted to eligible employees, directors and consultants. Terms regarding vesting period and contractual life of the 2016 Plan have not significantly changed from the terms of the 2015 Plan. Additionally, at the effective time of the Reorganization:

•

The 2015 Plan was terminated and no additional awards will be granted thereunder.

•

Each outstanding option to purchase 7.6 Class D common units of Fulgent LLC was cancelled in exchange for an equivalent option granted under the 2016 Plan to purchase one share of its common stock. The new options are subject to the same vesting schedule and other material terms and conditions as the cancelled options. The Reorganization was considered an incorporation pursuant to the terms of the 2015 Plan and the performance condition applicable to all options was deemed to have been satisfied. As a result, all of the options became immediately exercisable, to the extent vested, upon completion of the Reorganization. This satisfaction of the performance condition resulted in a cumulative stock-based compensation expense of $1,113 for the requisite service period, which the Company recorded during the period in which the Reorganization occurred. The remaining unrecognized stock-based compensation expense related to the options is being recorded over the remaining requisite vesting period of the awards using the accelerated attribution method.

•

Each outstanding restricted share unit relating to 7.6 Class D common units of Fulgent LLC was cancelled in exchange for an equivalent RSU granted under the 2016 Plan relating to one share of its common stock. The new RSUs are subject to the same vesting schedule and other material terms and conditions as the cancelled restricted share units. Equity-based compensation expense for RSUs is recognized ratably over the requisite vesting period of the awards.

•

Pursuant to the determination of the Manager of Fulgent LLC, the participation thresholds applicable to all Class D common units that constituted profits interests (i) were ignored and not applied in calculating the number of shares of the Company’s common stock that were issued in exchange for such units in the Reorganization, and (ii) did not carry over to such shares of the Company’s common stock. As a result, the holders of Fulgent LLC’s Class D common units that constituted profits interests received shares of the Company’s common stock in the Reorganization at the same ratio, 7.6-to-one, as the holders of Fulgent LLC’s Class D common units that were not subject to profits interest thresholds. Ignoring all profits interest thresholds upon the modification of the Class D common units that constitute profits interests into shares of the Company’s common stock resulted in a equity-based compensation expense of $1,353 that the Company recorded during the period in which the Reorganization occurred.

The following table summarizes the Company’s equity-based compensation expense for the three and nine months ended September 30, 2016 in the accompanying condensed consolidated statements of operations:

	For the Three Months Ended September 30, 2016		For the Nine Months Ended September 30, 2016
Cost of revenue	$	586	$	586
Research and development		959		959
Selling and marketing		396		396
General and administrative		552		2,178
Total	$	2,493	$	4,119

Award Activity

Option Awards

The following table summarizes activity for options to acquire common shares in the nine months ended September 30, 2016:

	Number of Shares Subject to Options		Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2015		274	$	0.38			$	645
Granted		324	$	1.18
Exercised		—		—
Forfeited/canceled		7	$	0.38
Outstanding as of September 30, 2016		591	$	0.82		9.3	$	5,034
Exercisable at September 30, 2016		80	$	0.38		9.3		708

The number of shares subject to options and weighted average exercise price in the table above have been adjusted to show the effects of the Reorganization. The weighted-average grant date fair value of options to acquire common shares granted in the nine months ended September 30, 2016 was $6.98. As of September 30, 2016, the remaining unrecognized compensation expense of $2.0 million related to these options is expected to be recognized over a weighted-average period of 3.1 years.

Share and Restricted Stock Unit Awards

The following table shows grants of share awards and grants of restricted stock units during the nine months ended September 30, 2016:

	Employee
Shares		328,947
Restricted Stock Units		65,789

The common shares issued in the nine months ended September 30, 2016 were related to one award granted to an employee in January 2016, and recorded based on the estimated fair value of common shares on the grant date which resulted in equity-based compensation expense of $1.6 million. These shares were granted outside of the Plan, were immediately vested and are not subject to a profits interest threshold. The restricted stock units issued in the nine months ended September 30, 2016 are recorded based on the fair value of common shares on the grant date which resulted in equity-based compensation expense of $770 to be recognized over four years. As of September 30, 2016, $27 has been recognized and the remaining unrecognized compensation expense of $743 related to these restricted stock units is expected to be recognized over a weighted-average period of 3.9 years.

Fair Value Assumptions

Option Awards to Employees

The following table sets forth weighted-average assumptions used to estimate the fair value of options to acquire common shares granted to employees during the nine months ended September 30, 2016:

Expected term (in years)	6.1
Risk-free interest rates	1.4	%
Dividend yield	0
Expected volatility	95.6	%

These assumptions and estimates are as follows:

•

Expected Term. The expected term represents the period that our equity-based awards are expected to be outstanding. We determine the expected term assumption based on the vesting terms, exercise terms and contractual terms of the options.

•

Risk-Free Interest Rate. The Company determines the risk-free interest rate by using the equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

•

Dividend Yield. The assumed dividend yield is based on the Company’s expectation that it will not pay dividends in the foreseeable future, which is consistent with its history of not paying dividends.

•

Expected Volatility. The Company does not have sufficient history to estimate the volatility of the price of its common stock or the expected term of its options. The Company calculates expected volatility based on historical volatility data of a representative group of companies that are publicly traded. The Company selected representative companies with comparable characteristics to it, including risk profiles and position within the industry, and with historical equity price information sufficient to meet the expected term of the equity-based awards. The Company computes the historical volatility of this selected group using the daily closing prices for the selected companies’ equity during the equivalent period of the calculated expected term of its equity-based awards. The Company will continue to use the representative group volatility information until the historical volatility of its equity is relevant to measure expected volatility for future option grants.

•

Forfeiture Rate. The Company has early adopted Accounting Standards Update No. 2016-09, Stock Compensation (Topic 718); Improvements to Employee Share-Based Payment Accounting, and has elected to account for forfeitures as they occur.

Option Awards to Non-Employees

Equity-based compensation expense related to options granted to non-employees is recognized as the options are earned. The fair value of the options is more reliably measurable than the fair value of the services received.

The fair value of non-employee options is calculated at each reporting date, using the Black-Scholes option-pricing model, until the award vests or there is a substantial incentive for the non-employee not to perform the required services.

The following table sets forth the weighted-average assumptions used to estimate the fair value of options to acquire common shares granted to non-employees during the nine months ended September 30, 2016:

Expected term (in years)	10
Risk-free interest rates	1.6	%
Dividend yield	0
Expected volatility	96.9	%

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes Income tax expense consists of federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Upon completion of the Reorganization, the Company converted from a pass-through entity for tax purposes to a taxable entity. The change in tax status resulted in the recognition of a deferred tax asset of $86 and a deferred tax liability of $503 for the initial temporary differences between book and tax, primarily from depreciation and equity-based compensation at the time of the change in status. No tax expense resulted as of the date of the Reorganization as it took place on the last day of quarter. Operational results attributed to that one day were deemed insignificant.

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events Initial Public Offering On October 4, 2016, the Company completed the IPO, in which it issued and sold an aggregate of 4,830 shares of common stock (including 630 shares issued and sold on October 7, 2016 pursuant to the underwriters’ exercise in full of their option to purchase additional shares) at a public offering price of $9.00 per share. The Company received net proceeds of approximately $36,258, after deducting underwriting discounts and commissions of $3,043 and other offering expenses paid or payable by the Company of approximately $4,169.

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors that management believes to be reasonable under the circumstances. Actual results could differ from these estimates. Significant items subject to such estimates and assumptions include revenue recognition criteria, the fair value of equity-based awards, accounts receivable and allowances for doubtful accounts, the useful lives of fixed assets and estimates of tax liabilities.
Reporting Segment and Geographic Information	Reporting Segment and Geographic Information Reporting segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its CEO. The Company views its operations and manages its business in one reporting segment.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. The Company provides for federal, state and foreign income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense. Prior to the Reorganization, Fulgent LLC was organized as a limited liability company and its members elected to have Fulgent LLC treated as a partnership for income tax purposes. All taxable income or loss and tax credits generally were reflected in the personal income tax returns of the Fulgent LLC’s members. Accordingly, no provision for federal and state income taxes was provided in the accompanying consolidated financial statements prior to the Reorganization. Pursuant to the Reorganization, the Company is a taxable entity. The change in tax status resulted in the recognition of a deferred tax asset in the amount of $86 and a deferred tax liability in the amount of $503 representing the initial temporary differences at the time of the change in status. The most significant components of the deferred tax asset and liability were the result of differences in book and tax depreciation and equity-based compensation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance The FASB continues to address certain implementation issues and clarify certain core revenue recognition principles of ASU 2014-09. In July 2015, the FASB voted to delay the effective date of this standard such that ASU 2014-09, as amended, will be effective for the Company for annual and interim periods beginning after December 15, 2017. Early adoption of the standard is permitted for annual periods beginning after December 15, 2016. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company is evaluating the effects of this standard on its financial position, results of operations and cash flows. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”), which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, including a provision that requires equity investments (except for investments accounted for under the equity method of accounting) to be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 is effective for the Company in the first quarter of 2018, with early adoption permitted. The Company is currently evaluating the effect that ASU 2016-01 will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The update is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for interim and annual reporting periods beginning with the year ending December 31, 2019. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows. The standard clarifies the way certain cash receipts and cash payments are classified with the objective of reducing the existing diversity in practice. The standard is effective for fiscal years and interim periods beginning after December 15, 2017. Early adoption is permitted for all periods beginning after December 15, 2016. The Company is currently evaluating the impact of adopting this standard.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Overview and Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Major Components of Statements of Operations Data Comprising Income (Loss) on Discontinued Operations

The major components of statements of operations data comprising the income (loss) on discontinued operations are as follows:

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2016		2015			2016			2015
Operating expenses:
Research and development	$	-	$	732		$	350		$	1,220
General and administrative		-		89			9			900
Total operating expenses		-		821			359			2,120
Operating Income (loss)		-		(821	)		(359	)		(2,120	)
Interest and other income (expense)		-		-			400			(1	)
Income (loss)	$	-	$	(821	)	$	41		$	(2,121	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Calculation of Basic and Diluted Income (Loss) Per Share

	Three Months Ended								Nine Months Ended
	Continuing Operations			Discontinued Operations		Total			Continuing Operations			Discontinued Operations		Total
Income (loss)	$	(1,107	)	$	0	$	(1,107	)	$	(6,201	)	$	41	$	(6,160	)
Deemed dividend on redemption of Class D-1 preferred unit						$	0		$	(3,727	)			$	(3,727	)
Distribution to Class D-1 preferred unitholder	$	(4,592	)			$	(4,592	)	$	(4,592	)			$	(4,592	)
Income (loss) allocable to common shareholders	$	(5,699	)	$	0	$	(5,699	)	$	(14,520	)	$	41	$	(14,479	)
Income (loss) allocated to common shareholders	$	(5,699	)						$	(14,520	)
Income (loss) allocated to Class P common units													18
Income (loss) allocated to Class P preferred units													23
Weighted-average common shares—outstanding, basic and diluted		12,846			—					12,455			—
Weighted-average Class P common units outstanding, basic and diluted		—			—					—			13,522
Weighted-average Class P preferred units outstanding, basic and diluted		—			—					—			17,682
Income (loss) per common share from continuing operations, basic and diluted	$	(0.44	)		—				$	(1.17	)		—
Income per Class P common unit, basic and diluted		—			—					—			—
Income per Class P preferred unit, basic and diluted		—			—					—			—

Anti-dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share

The following securities have been excluded from the calculation of diluted income (loss) per share for all periods presented because their effect would have been anti-dilutive:

	Three Months Ended				Nine Months Ended
	Continuing Operations		Discontinued Operations		Continuing Operations		Discontinued Operations
Common share options		591		—		591		—
Common share restricted stock units		66				66
Class P common unit options		—		—		—		1,810

Fixed Assets (Tables)

9 Months Ended

Sep. 30, 2016

Property Plant And Equipment [Abstract]

Major Classes of Fixed Assets

Major classes of fixed assets were as follows:

	Useful Lives	September 30, 2016			December 31, 2015
Computer hardware	3 Years	$	1,003		$	601
Computer software	3 Years		318			176
Machinery and equipment	5 Years		177			210
Medical lab equipment	5 Years		4,678			2,016
General equipment	3 Years		59			59
Furniture and fixtures	5 Years		86			51
Leasehold improvements	Shorter of lease term or estimated useful life		485			256
Sub-Total		$	6,806		$	3,369
Accumulated depreciation			(1,628	)		(900	)
		$	5,178		$	2,469

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2016

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following:

	September 30, 2016		December 31, 2015
Deferred initial public offering costs	$	4,169	$	—
Reagents		525		212
Prepaid expenses		183		65
Payroll tax refund		6		37
Total	$	4,883	$	314

Reporting Segment and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Summary of Revenue by Geographic Region

Revenue by region was as follows:

		For the Three Months Ended September 30,			For the Nine Months Ended September 30,
	2016		2015		2016		2015
Revenue:
United States	$	2,147	$	1,559	$	6,283	$	3,500
Foreign:
Canada		937		801		2,676		2,176
China		1,148				1,148
Other Countries		779		545		2,315		999
	$	5,011	$	2,905	$	12,422	$	6,675

Members' / Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Summary of Units of Fulgent LLC Cancelled in Exchange for Shares of Common Stock

The following is a summary of the units of Fulgent LLC that were cancelled in exchange for shares of the Company’s common stock:

	Pre-Reorganization
Class D-1 preferred units		51,382
Class D-2 preferred units		15,395
Class D common units		2,500
Class D common units — profit interests		28,355
		97,632

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

+ Details

Equity-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Equity-Based Compensation

	For the Three Months Ended September 30, 2016		For the Nine Months Ended September 30, 2016
Cost of revenue	$	586	$	586
Research and development		959		959
Selling and marketing		396		396
General and administrative		552		2,178
Total	$	2,493	$	4,119

Summary of Activity for Options to Acquire Common Shares

The following table summarizes activity for options to acquire common shares in the nine months ended September 30, 2016:

	Number of Shares Subject to Options		Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2015		274	$	0.38			$	645
Granted		324	$	1.18
Exercised		—		—
Forfeited/canceled		7	$	0.38
Outstanding as of September 30, 2016		591	$	0.82		9.3	$	5,034
Exercisable at September 30, 2016		80	$	0.38		9.3		708

Summary of Grants of Share Awards and Grants of Restricted Stock Units

The following table shows grants of share awards and grants of restricted stock units during the nine months ended September 30, 2016:

	Employee
Shares		328,947
Restricted Stock Units		65,789

Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Common Shares

The following table sets forth weighted-average assumptions used to estimate the fair value of options to acquire common shares granted to employees during the nine months ended September 30, 2016:

Expected term (in years)	6.1
Risk-free interest rates	1.4	%
Dividend yield	0
Expected volatility	95.6	%

Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Common Shares Granted to Non-Employees

Expected term (in years)	10
Risk-free interest rates	1.6	%
Dividend yield	0
Expected volatility	96.9	%

Overview and Basis of Presentation - Additional Information (Details) - USD ($)			9 Months Ended
	Oct. 07, 2016	Oct. 04, 2016	Sep. 30, 2016
Description Of Business And Basis Of Presentation [Line Items]
Place of incorporation			Delaware
Date of incorporation			May 13, 2016
Date of corporate name change			Aug. 02, 2016
Subsequent Event \| Common Stock \| IPO
Description Of Business And Basis Of Presentation [Line Items]
Stock issued and sold (in shares)		4,830,000
Stock price per share		$ 9.00
Proceeds from issuance of shares		$ 36,258,000
Underwriting discounts and commissions		3,043,000
Other offering expenses		$ 4,169,000
Subsequent Event \| Common Stock \| Over Allotment Option
Description Of Business And Basis Of Presentation [Line Items]
Stock issued and sold (in shares)	630,000
Fulgent Therapeutics LLC
Description Of Business And Basis Of Presentation [Line Items]
Ownership percentage in subsidiary			100.00%
Date of reorganization			Sep. 30, 2016
Units cancelled in exchange for one share of common stock			7.6
Share of common stock exchanged for seven point six units			1
Gain (loss) on reorganization			$ 0
Fulgent Therapeutics LLC \| Maximum
Description Of Business And Basis Of Presentation [Line Items]
Options to acquire units cancelled in exchange for company’s common stock			591,112,000
Fulgent Therapeutics LLC \| Restricted Stock Units (RSUs)
Description Of Business And Basis Of Presentation [Line Items]
Units cancelled in exchange for restricted stock units relating to company’s common stock			65,789,000
Fulgent Therapeutics LLC \| Class D-1 Preferred Units
Description Of Business And Basis Of Presentation [Line Items]
Number of common stock shares exchanged for cancelled units			6,761,000
Fulgent Therapeutics LLC \| Class D-2 Preferred Units
Description Of Business And Basis Of Presentation [Line Items]
Number of common stock shares exchanged for cancelled units			2,026,000
Fulgent Therapeutics LLC \| Class D Common Units
Description Of Business And Basis Of Presentation [Line Items]
Number of common stock shares exchanged for cancelled units			4,060,000

Overview and Basis of Presentation - Major Components of Statements of Operations Data Comprising Income (Loss) on Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating expenses:
Research and development	$ 732	$ 350	$ 1,220
General and administrative	89	9	900
Total operating expenses	821	359	2,120
Operating Income (loss)	(821)	(359)	(2,120)
Interest and other income (expense)		400	(1)
Income (loss)	$ (821)	$ 41	$ (2,121)

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Summary of Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($) Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of reporting segments \| Segment	1
Federal and state tax expense (benefit) prior to reorganization.	$ 0
Deferred tax liability	503,000
Deferred tax asset	$ 86,000

Income (Loss) Per Share - Additional Information (Details) - Fulgent Therapeutics LLC	9 Months Ended
	Sep. 30, 2016 shares
Earnings Per Share Basic And Diluted [Line Items]
Units cancelled in exchange for one share of common stock	7.6
Share of common stock exchanged for seven point six units	1

Income (Loss) Per Share - Calculation of Basic and Diluted Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Earnings Per Share Basic And Diluted [Line Items]

Income (loss), continuing operations

$ (1,107)

$ 1,180

$ (6,201)

$ 2,352

Continuing operations—common stock

$ (0.44)

$ 0

^[1]

$ (1.17)

$ 0

^[1]

Income (loss) from discontinued operations

$ 0

$ (821)

$ 41

$ (2,121)

Income (loss)

(1,107)

$ 359

(6,160)

$ 231

Income (loss) allocable to common shareholders

$ (5,699)

$ (14,479)

Weighted-average common shares—outstanding—basic and diluted

12,846

12,455

Continuing Operations

Earnings Per Share Basic And Diluted [Line Items]

Income (loss) allocable to common shareholders

$ (5,699)

$ (14,520)

Income (loss) allocated to common shareholders

$ (5,699)

$ (14,520)

Weighted-average common shares—outstanding—basic and diluted

12,846

12,455

Income (loss) per common share from continuing operations, basic and diluted

$ (0.44)

$ (1.17)

Discontinued Operations

Earnings Per Share Basic And Diluted [Line Items]

Income (loss) allocable to common shareholders

$ 0

$ 41

Class P Common Units | Discontinued Operations

Earnings Per Share Basic And Diluted [Line Items]

Income (loss) allocated to common units

$ 18

Weighted-average common shares—outstanding—basic and diluted

13,522

Class P Preferred Units | Discontinued Operations

Earnings Per Share Basic And Diluted [Line Items]

Income (loss) allocated to preferred units

$ 23

Weighted-average common shares—outstanding—basic and diluted

17,682

Class D-1 Preferred Units

Earnings Per Share Basic And Diluted [Line Items]

Deemed dividend on redemption of Class D-1 preferred unit

$ (3,727)

Distribution to Class D-1 preferred unitholder

(4,592)

Class D-1 Preferred Units | Continuing Operations

Earnings Per Share Basic And Diluted [Line Items]

Deemed dividend on redemption of Class D-1 preferred unit

(3,727)

Distribution to Class D-1 preferred unitholder

$ (4,592)

[1]	Basic and diluted income (loss) per common share was calculated prospectively from the date the Class D common units were issued in the October 2015 Recapitalization.

Income (Loss) Per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share (Details) - shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Common Share \| Options \| Continuing Operations
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from continuing operations of diluted income (loss) per share	591	591
Common Share \| Restricted Stock Units \| Continuing Operations
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from continuing operations of diluted income (loss) per share	66	66
Class P Common Units \| Discontinued Operations
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from continuing operations of diluted income (loss) per share		1,810

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 6,806	$ 3,369
Accumulated depreciation	(1,628)	(900)
Fixed assets, net	5,178	2,469
Computer hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,003	601
Useful life in years	3 years
Computer software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 318	176
Useful life in years	3 years
Machinery and equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 177	210
Useful life in years	5 years
Medical lab equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 4,678	2,016
Useful life in years	5 years
General equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 59	59
Useful life in years	3 years
Furniture and fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 86	51
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 485	$ 256
Useful life in years	Shorter of lease term or estimated useful life

Fixed Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 304	$ 171	$ 750	$ 385

Other Current Assets - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Deferred initial public offering costs	$ 4,169
Reagents	525	$ 212
Prepaid expenses	183	65
Payroll tax refund	6	37
Total	$ 4,883	$ 314

Other Current Liabilities - Additional Information (Details) $ in Millions	Sep. 30, 2016 USD ($)
Fulgent Therapeutics LLC \| Other Current Liabilities
Other Current Liabilities [Line Items]
Accrued tax distributions	$ 1.3

Reporting Segment and Geographical Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2016 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 5,011	$ 2,905	$ 12,422	$ 6,675
United States
Segment Reporting Information [Line Items]
Revenue	2,147	1,559	6,283	3,500
Canada
Segment Reporting Information [Line Items]
Revenue	937	801	2,676	2,176
China
Segment Reporting Information [Line Items]
Revenue	1,148		1,148
Other Countries
Segment Reporting Information [Line Items]
Revenue	$ 779	$ 545	$ 2,315	$ 999

Major Customers and Accounts Receivable - Additional information (Detail) - Customer Concentration Risk - Customer			3 Months Ended		9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue
Concentration Risk [Line Items]
Concentration risk, percentage			23.00%	0.00%
Number of customers			1	1	0	0
Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	26.00%
Number of customers	1	0

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Operating leases, rent expense	$ 55	$ 47	$ 179	$ 115

Members' / Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Millions		1 Months Ended	9 Months Ended
	Sep. 30, 2016 USD ($) Vote $ / shares shares	Sep. 30, 2016 USD ($) Vote $ / shares shares	Sep. 30, 2016 USD ($) Vote $ / shares shares
Class Of Stock [Line Items]
Common stock, shares authorized	200,000,000	200,000,000	200,000,000
Common stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding	0	0	0
Return of capital contribution \| $		$ 4.6
Class D Common and Preferred Units
Class Of Stock [Line Items]
Tax distribution to former LLC members \| $	$ 1.3
Reorganization \| Common Stock
Class Of Stock [Line Items]
Cancelled in exchange for common units			12,846,000
Reorganization \| Common Stock and Additional Paid-in Capital
Class Of Stock [Line Items]
Conversion of members' interests \| $			$ 72.0
Fulgent Therapeutics LLC
Class Of Stock [Line Items]
Units cancelled in exchange for one share of common stock			7.6
Share of common stock exchanged for seven point six units			1
Certificate of Incorporation
Class Of Stock [Line Items]
Common stock, shares authorized	200,000,000	200,000,000	200,000,000
Common stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding	0	0	0
Certificate of Incorporation \| Common Stock
Class Of Stock [Line Items]
Number of vote per share held \| Vote	1	1	1

Members' / Stockholders' Equity - Summary of Units of Fulgent LLC Cancelled in Exchange for Shares of Common Stock (Details)	9 Months Ended
	Sep. 30, 2016 shares
Class Of Stock [Line Items]
Pre-Reorganization	97,632
Class D-1 Preferred Units
Class Of Stock [Line Items]
Pre-Reorganization	51,382
Class D-2 Preferred Units
Class Of Stock [Line Items]
Pre-Reorganization	15,395
Class D Common Units
Class Of Stock [Line Items]
Pre-Reorganization	2,500
Class D Common Units - Profit Interests
Class Of Stock [Line Items]
Pre-Reorganization	28,355

Equity-Based Compensation - Additional Information (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2016 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	$ 2,493,000	$ 4,119,000
Weighted- Average Exercise Price Per Share, Granted \| $ / shares		$ 1.18
Class D Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense		$ 1,353,000
Class D Common Units \| Fulgent Therapeutics LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cancellation of common stock ratio		0.1316
2015 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option vesting period		4 years
Stock option expiration period		10 years
Equity-based compensation expense		$ 0
2015 Equity Incentive Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense		$ 1,113,000
2016 Omnibus Incentive Plan \| Class D Common Units \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cancellation of common stock ratio		0.1316
2016 Omnibus Incentive Plan \| Employees Directors and Consultants \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for issuance under the plan \| shares		2,038,000
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense		$ 27,000
Expected to be recognized, weighted-average period		3 years 10 months 24 days
Total compensation cost not yet recognized on grant date	770,000	$ 770,000
Compensation cost not yet recognized on grant date, period for recognition		4 years
Unrecognized compensation expense	743,000	$ 743,000
Restricted Stock Units (RSUs) \| 2015 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option vesting period		4 years
Restricted Stock Units (RSUs) \| 2016 Omnibus Incentive Plan \| Class D Common Units \| Fulgent Therapeutics LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cancellation of common stock ratio		0.1316
Option Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted- Average Exercise Price Per Share, Granted \| $ / shares		$ 6.98
Unrecognized compensation expense	$ 2,000,000	$ 2,000,000
Expected to be recognized, weighted-average period		3 years 1 month 6 days
Share and Restricted Stock Unit Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense		$ 1,600,000

Equity-Based Compensation - Summary of Equity-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 2,493	$ 4,119
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	586	586
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	959	959
Selling and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	396	396
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 552	$ 2,178

Equity-Based Compensation - Summary of Activity for Options to Acquire Common Shares (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Subject to Options, Outstanding as of December 31, 2015	274
Number of Shares Subject to Options, Granted	324
Number of Shares Subject to Options, Forfeited/canceled	7
Number of Shares Subject to Options, Outstanding as of September 30, 2016	591
Number of Shares Subject to Options, Exercisable at September 30, 2016	80
Weighted- Average Exercise Price Per Share, Outstanding as of December 31, 2015	$ 0.38
Weighted- Average Exercise Price Per Share, Granted	1.18
Weighted- Average Exercise Price Per Share, Forfeited/canceled	0.38
Weighted- Average Exercise Price Per Share, Outstanding as of September 30, 2016	0.82
Weighted- Average Exercise Price Per Share, Exercisable at September 30, 2016	$ 0.38
Weighted- Average Remaining Contractual Life (in years), Outstanding as of September 30, 2016	9 years 3 months 18 days
Weighted- Average Remaining Contractual Life (in years), Exercisable at September 30, 2016	9 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 5,034	$ 645
Aggregate Intrinsic Value, Exercisable at September 30, 2016	$ 708

Equity-Based Compensation - Summary of Grants of Share Awards and Grants of Restricted Stock Units (Details)	9 Months Ended
	Sep. 30, 2016 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares	324,000
Share and Restricted Stock Unit Awards \| Employee
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares	328,947,000
Restricted Stock Units	65,789,000

Equity-Based Compensation - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Common Shares (Details) - Option Awards	9 Months Ended
	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 6 days
Risk-free interest rates	1.40%
Dividend yield	0.00%
Expected volatility	95.60%

Equity-Based Compensation - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Common Shares Granted to Non-Employees (Details)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (in years)	10 years
Risk-free interest rates	1.60%
Dividend yield	0.00%
Expected volatility	96.90%

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Taxes [Line Items]
Deferred tax asset	$ 86,000		$ 86,000
Deferred tax liability	503,000		503,000
Tax expense	417,000	$ 0	$ 417,000	$ 0
Reorganization
Income Taxes [Line Items]
Tax expense	$ 0

Subsequent Events - Additional Information (Details) - Subsequent Event - Common Stock - USD ($) $ in Thousands	Oct. 07, 2016	Oct. 04, 2016
IPO
Subsequent Event [Line Items]
Stock issued and sold (in shares)		4,830,000
Proceeds from issuance of shares		$ 36,258
Underwriting discounts and commissions		3,043
Other offering expenses		$ 4,169
Over Allotment Option
Subsequent Event [Line Items]
Stock issued and sold (in shares)	630,000